

specification at page 34, line 26. This amendment has not limited the scope of the claimed invention, because a skilled artisan would understand the terms to be equivalent.

The Examiner has rejected claim 5 under 35 U.S.C. §112, ¶2 on the asserted basis that the term "roughly" is relative, and thus renders the claim indefinite. While relative terms are not per se indefinite, Applicants have amended claim 5 to delete the term "roughly" in order to advance the prosecution of this case. This amendment has not limited the scope of the claimed invention as the term "roughly" was originally included to simply reflect protection that would be otherwise affordable under the doctrine of equivalents. By removing this term, literally, from the claim, Applicants do not intend to forfeit legitimate protection afforded under the doctrine of equivalents.

OK
The Examiner has rejected claim 5 under 35 U.S.C. §112, ¶2 on the asserted basis that the term "discrete pocket" is indefinite. Applicants respectfully submit that the rejection is improper. The specification provides the skilled artisan with more than ample direction as to the meaning of this term. Specifically, the discrete pocket at issue is described in the specification at page 34, lines 22-28, and is further illustrated in the X-ray structure provided in Figure 1. Additionally, the specification illustrates how such X-ray data can be obtained (see page 33, line 22 to page 16). Section 112 requires no more. Applicants respectfully request that the Examiner withdraw the rejection.

Applicants have amended claim 5 to clarify that the amino acid residues defining the discrete pocket at issue are those "designated" as Phe 16, Tyr 19, Met 20, Val 23, Val 25, Ala 33, Phe 57, Thr 74, Ala 75, Asp 76, Arg 78. Support for this amendment can be found in the specification at page 3 line 10, and also in original claim 3—which indicate that the residue positions provided in this application are Applicants' own designations. Thus, when compared against the human aP2 sequence listing previously provided by Applicants, the Examiner will note that the positions of these amino acid residues are shifted by one position. This is due to the fact that the laboratory procedures used by Applicants to characterize the protein resulted in the cleavage of the first residue (Met) of the full sequence. One skilled in the art would understand this. ✓
given the shift, does this still retain binding specificity & activity?

The Examiner has rejected claim 3 and 4 under 35 U.S.C. §112, ¶2 on the asserted basis that the term "hydrogen bond donator or acceptor" would not be clearly understood by the skilled artisan. In support of this assertion the Examiner provides various meanings for the terms "proton donor/acceptor". Applicants respectfully submit that the rejection is improper. One skilled in the art would recognize that the term "hydrogen bond donator or acceptor" is distinct from the term "proton

donor or acceptor." The latter term denotes a Bronsted-Lowry acid base reaction in which a proton (an ionized hydrogen atom) is transferred covalently from one molecule to another (as in the reaction of HCl with NaOH to give H₂O and NaCl). Hydrogen binding is somewhat different. As described in the standard organic chemistry textbook "Advanced Organic Chemistry" by March (Applicants intend to provide the Examiner with a copy of this reference shortly in a supplemental filing), a hydrogen bond is "a bond between a functional group A-H and an atom or group of atoms B in the same or a different molecule. With exceptions to be noted later, hydrogen bonds are formed only when A is oxygen, nitrogen, or fluorine and when B is oxygen, nitrogen, or fluorine." These attractive forces have energies on the order of 2-10 kcal/mol. In the book "Peptide Chemistry" by Bodansky (Applicants intend to provide the Examiner with a copy of this reference shortly in a supplemental filing), it is stated that "In the hydrogen bond, the hydrogen atom belongs, to some extent, to both electronegative [i.e. O, N, F, S] atoms." Many organic heteroatoms have the capacity to either donate and/or accept (i.e. participate) covalently bound hydrogens with other heteroatoms. Examples would include: C=O ----H-N, CO-O----H-N, and CO-O-H----N-, where ---- represents the hydrogen bond and - represents a covalent bond. These are very common interactions found between ligands (e.g. inhibitors) and proteins (e.g. receptors, enzymes, etc.). Applicants respectfully submit that one skilled in the art would readily understand the term "hydrogen bond donor or acceptor". ?

The Rejection Under 35 U.S.C. §103

The Examiner has rejected claims 1-11 and 14-15 under 35 U.S.C. §103 as being unpatentable over Hotamisligil et al. in view of Failli et al. (US 5,218,124). Applicants respectfully submit that the rejection is improper.

The Examiner supports this rejection on the asserted basis that Failli teaches that certain oxazole derivative compounds, including the elected compound, are known aP2 inhibitors. This is factually incorrect. Failli teaches that the compounds at issue are inhibitors of phospholipase A₂ (see Failli at column 1, lines 13-14). The enzyme Phospholipase A₂ (also referred to as PLA₂—see enclosed definition from Acronyms, Initialisms & Abbreviations Dictionary), is different from Adipocyte Fatty Acid Binding Protein (aP2) (which is not an enzyme). While the acronyms may be similar, the targets at issue are very different. Applicants respectfully request that the Examiner withdraw this rejection, which is founded on a faulty premise.

RECEIVED

JUN 28 2001


TECH CENTER 1600/2900

Conclusion

Applicants request that the Examiner withdraw the rejections of record, reconsider the case and allow all pending claims for allowance in view of the above amendments and remarks.

Respectfully submitted,

Bristol-Myers Squibb Company
Patent Department
P.O. Box 4000
Princeton, NJ 08543-4000
(609) 252-5781


Ronald S. Hermenau
Attorney for Applicants
Reg. No. 34,620

Date: 6/21/01



APPENDIX

COPY OF MARKED-UP AMENDED CLAIMS

RECEIVED

JUN 28 2001

TECH CENTER 1600/2900

5. The method as defined in Claim 3 where said aP2 inhibitor contains an additional substituent which binds to ~~(in)~~within and/or interacts with a discrete pocket within the aP2 protein defined roughly by the amino acid residues designated Phe I6, Tyr I9, Met 20, Val 23, Val 25, Ala 33, Phe 57, Thr 74, Ala 75, Asp 76, Arg 78 in human aP2.



RECEIVED
JUN 28 2001

JUN 28 2001

TECH CENTER 1600/2900

Acronyms, Initialisms & Abbreviations Dictionary

*A Guide to Acronyms, Abbreviations,
Contractions, Alphabetic Symbols, and Similar Condensed Appellations*

Covering: Aerospace, Associations, Banking, Biochemistry, Business, Data Processing,
Domestic and International Affairs, Economics, Education, Electronics, Genetics,
Government, Information Technology, Internet, Investment, Labor, Law, Medicine, Military Affairs,
Pharmacy, Physiology, Politics, Religion, Science, Societies, Sports, Technical
Drawings and Specifications, Telecommunications, Trade, Transportation, and Other Fields

28th Edition

Volume 1

Part 3

P-Z

Mary Rose Bonk,
Editor

Pamela Dear,
Associate Editor



GALE GROUP

Detroit
New York
San Francisco
London
Boston
Woodbridge, CT

Editor: Mary Rose Bonk

Associate Editor: Pamela Dear

Assistant Editor: Phyllis Spinelli

Data Capture Manager: Ronald D. Montgomery

Project Administrator: Gwendolyn S. Tucker

Data Capture Specialists: Beverly Jendrowski, Constance Wells

Manufacturing Manager: Dorothy Maki

Buyer: NeKita McKee

Graphic Services Manager: Barbara J. Yarrow

Graphic Artist: Mike Logusz

Director, Technical Support Services: Theresa A. Rocklin

Senior Programmer: Charles Beaumont

Programmer/Analyst: Magdalena Cureton

TRADEMARKS AND PROPRIETARY RIGHTS

Acronyms, Initialisms, and Abbreviations Dictionary, its supplement, *Acronyms, Initialisms, and Abbreviations Dictionary Supplement*, and its companion volume, *Reverse Acronyms, Initialisms, and Abbreviations Dictionary*, are not, and are not intended to be in any way, sources of legal authority. The inclusion of an acronym, initialism, or abbreviation (acronym) does not represent an expression of the publisher's opinion as to any legal rights, trademark or otherwise, in such acronym, nor should it be relied upon as having any bearing on the validity or ownership of any trademark. The failure to indicate that an acronym is a trademark is not intended as a representation by the publisher that no trademark right exists in the acronym and does not affect any legal rights in such acronym. A reference to an owner of an acronym or to an acronym as a trademark likewise should not be relied on for legal authority.

While every effort has been made to ensure the reliability of the information presented in this publication, Gale Group does not guarantee the accuracy of the data contained herein. Gale accepts no payment for listing; and inclusion in the publication of any organization, agency, institution, publication service, or individual does not imply endorsement of the editors or publisher.

Errors brought to the attention of the publisher and verified to the satisfaction of the publisher will be corrected in future editions.

This publication is a creative work fully protected by all applicable copyright laws, as well as by misappropriation, trade secret, unfair competition, and other applicable laws. The authors and editors of this work have added value to the underlying factual material herein through one or more of the following: unique and original selection, coordination, expression, arrangement, and classification of the information.

Gale Group and design is a trademark used herein under license. All rights to this publication will be vigorously defended.

Copyright © 2001 by Gale Group, Inc.
27500 Drake Rd.
Farmington Hills, MI 48331-3535

Library of Congress Catalog Card Number 84-643188

ISBN 0-7876-3381-X (Volume 1 Complete)

ISBN 0-7876-3382-8 (Part 1: A-F only)

ISBN 0-7876-3383-6 (Part 2: G-O only)

ISBN 0-7876-3384-4 (Part 3: P-Z only)

ISSN 0270-4404

Printed in the United States of America

PL PLC Capital LLC, Inc. [NYSE symbol]
 PL Pleadings [Legal shorthand] (LWAP)
 PL Pleasure (ROG)
 PL [The] Plessey Co. Ltd. (MCD)
 PL Pleural [Medicine] (MAE)
 PL Plimsoll Line [Shipping] (DAS)
 PL Ploshchad [Square] [Russian] (EY)
 PL Plowden's English King's Bench Commentaries [or Reports]
 [1550-80] [A publication] (DLA)
 PL Plug (AAG)
 PL Plume [Numismatics]
 PL Plural
 PL Plural (ODBW)
 PL Plymouth [Postcode] (ODBW)
 PL Poet Laureate
 PL Poetry London [A publication British]
 PL Poiseuille [Unit of dynamic viscosity]
 PL Poland [ANSI two-letter standard code] (CNC)
 PL Poland [MARC country of publication code Library of Congress]
 (LCCP)
 PL Poland (MILB)
 PL Polarized Light
 PL Policy Loan
 PL Poly-L-lysine [Also, PLL] [Biochemical analysis]
 PL Poor Law [A publication] (DLA)
 PL Portable Low-Power [Reactor] (NRCH)
 PL Port Line [Steamship] (MHDW)
 PL Position Line [Navigation]
 PL Position Location [DoD]
 PL Post Landing [NASA] (KSC)
 PL Post Laundry [Army]
 PL Power Line (IAA)
 PL Power Loading (IAA)
 PL Power Locks (BARN)
 PL Prayers for Life (EA)
 PL Prelaunch (NASA)
 PL Preliminary Leaf [Bibliography]
 PL Presentation Label [Publishing]
 PL Presley Labs [Vancouver Stock Exchange symbol]
 PL Pressurizer Level (IEEE)
 PL Price Level [Economics]
 PL Price List
 PL Primary Leading [Photography] (DGA)
 PL Primrose League [British] (DI)
 PL Prince Line [Steamship] (MHDW)
 PL Princess Louise's Sutherland and Argyll Highlanders [Military
 British] (ROG)
 PL Private Label [Business term]
 PL Private Line
 PL Procedural Language (PCM)
 PL Procedure Library [Computer science]
 PL Production Language
 PL Production List (AAG)
 PL Product Liability [Insurance]
 PL Product License
 PL Profit and Loss [Accounting]
 PL Program Level (IAA)
 PL Program Library [Computer science]
 PL Program Logic [Computer science] (TEL)
 PL Programming Language [Computer science]
 PL Progressive Labor [A faction of Students for a Democratic Society]
 PL Projection Lens [Microscopy]
 PL Project Leader
 PL Project Lighthawk [Later, LH] (EA)
 PL Project Local [Defunct] (EA)
 PL Prolymphocytic Leukemia [Also, PLL] [Oncology]
 PL Promotion List (DIC)
 PL Propagation Loss
 PL Propellant Loading [NASA] (KSC)
 PL Property Line [Real estate] (MSA)
 PL Proportional Limit
 PL Proprietary Limited (ADA)
 PL Propulsion Laboratory [Army] (GRD)
 PL Prospective Loss
 PL Protected Location [Shipping] (DS)
 PL Protective Life Corp. [NYSE symbol] (SPSG)
 PL Protectively Located [Plant layout]
 PL Provisioning List (MCD)
 PL Pseudolumina [Anatomy]
 PL Psychological Laboratory (MCD)
 PL Public Law [An act of Congress]
 PL Public Liability [Business term]
 PL Public Library
 PL Pulmonary Venous Pressure [Medicine] (MAE)
 PL Pulpolingual [Dentistry]
 PL Pulsatility Index [Medicine]
 PL Pulse Length (NVT)
 PL Purchased Labor (NASA)
 PL Pyridoxal [Also, Pxl] [Biochemistry]
 PL Radio Positioning Land Station [ITU designation] (CET)
 PL Transpulmonary Pressure [Cardiology] (DAVI)
 PL Programming Language, Version One [Computer science] (MCD)
 PL Pakistan Liberation Army (PD)
 PL Palau [Palau Islands] [Seismograph station code, US Geological
 Survey Closed] (SEIS)

PLA Palestine Liberation Army
 PLA Parachute Location Aid (MCD)
 PLA Para Legal Association [British] (DBA)
 PLA Parlamento Latinoamericano [Latin American Parliament - LAP]
 [Bogota, Colombia] (EAIO)
 PLA Parlar Resources Ltd. [Vancouver Stock Exchange symbol]
 PLA Partido Laborista Agrario [Panama] [Political party] (EY)
 PLA Partido Liberal Autentico [Panama] [Political party] (EY)
 PLA Party of Labor of Albania [Political party] (PPW)
 PLA Passengers' Luggage in Advance [Railway] (ROG)
 PLA Patriotic Liberation Army [Myanmar] (PD)
 PLA Pedestrian League of America [Later, APA] (EA)
 Pla Pelagius [Deceased, 1232] [Authority cited in pre-1607 legal
 work] (DSA)
 PLA Pennilane Development [Vancouver Stock Exchange symbol]
 PLA People's Liberation Army [National Liberation Front] [North
 Vietnam] (VNW)
 PLA People's Liberation Army [China]
 PLA People's Liberation Army [India] (PD)
 PLA Pet Lovers Association (EA)
 PLA Phase Locked Arrays [Physics]
 PLA Philatelic Literature Association [Later, APRL] (EA)
 PLA Phospholipase A [An enzyme] (DAVI)
 PLA Physiological Learning Aptitude (KSC)
 PLA Pitch Lock Actuator (MCD)
 PLA Place (ADA)
 PLA Placebo [Medicine]
 Pla Placentinus [Deceased, 1192] [Authority cited in pre-1607 legal
 work] (DSA)
 PLA Placita
 PLA Placitum [or Placita] [Agreeable, Agreed Upon] [Latin] [Legal term]
 (DLA)
 PLA Plain Language Address [Telecommunications] (TEL)
 PLA Planned Labor Application [Military] (AFIT)
 PLA Planned Landing Area [NASA]
 PLA Plan of Launch Azimuth [Aerospace] (AAG)
 pla Plaster (VRA)
 PLA Platelet Antigen (DB)
 PLA Playboy Enterprises CI'B' [NYSE symbol] (TTSB)
 PLA Playboy Enterprises, Inc. [NYSE symbol] (SPSG)
 PLA Plaza (ADA)
 PLA Poetry League of America (EA)
 PLA Polylactic Acid [Organic chemistry] (RDA)
 PLA Poly-L-arginine [Biochemistry]
 PLA Polynesian Air-Ways [ICAO designator] (FAAC)
 PLA Popular Library of Art [A publication]
 PLA Port of London Authority [British]
 PLA Posterior Left Atrial Wall [Cardiology]
 PLA Potential Leaf Area [Botany]
 PLA Potentially Lethal Arrhythmia [Medicine] (DMAA)
 PLA Power Lever Angle
 PLA Practice Landing Approach [Aviation]
 PLA Price-Level-Adjusted Accounting (ADA)
 PLA Print Load Analyzer
 PLA Private Libraries Association [British]
 PLA Product License Application [FDA]
 PLA Professional Legal Assistants (EA)
 PLA Program-Length Advertising [Broadcasting] (WDMC)
 PLA Programmable Line Adapter
 PLA Programmable Logic Array [Computer science]
 PLA Programmed Logic Array (NITA)
 PLA Project Labor Agreement (AAGC)
 PLA Proton Linear Accelerator
 PLA Psycholinguistic Age [Education]
 PLA Psychological Learning Aptitude (MCD)
 PLA Public Library Association (EA)
 PLA Pulpolabial [Dentistry]
 PLA Pulpolingual [Dentistry]
 PLA Pulsed LASER Annealing [Semiconductor technology]
 PLA Pulverized Limestone Association (EA)
 PLA University of Pittsburgh, Law School, Pittsburgh, PA [OCLC
 symbol] (OCLC)
 PLA₂ Phospholipase A₂ [An enzyme]
 PLAA Playboy Enterprises A' (vtg) [NYSE symbol] (TTSB)
 PLAA Positive Low Angle of Attack
 PLA AEPS PLA [Public Library Association] Alternative Education Programs
 Section
 PLAAF People's Liberation Army Air Force
 PLA AFLS PLA [Public Library Association] Armed Forces Library Section
 PLAA Packaged Liquid Air-Augmented Rocket (MCD)
 PLAA Plasma Atomic Absorption System [Spectrometry]
 PLA AV PLA [Public Library Association] Audiovisual
 PLA AVC PLA [Public Library Association] Audiovisual Committee
 PLAB Party-Line Adapter Board [Telecommunications] (MHD)
 PLAB Photonics, Inc. [NASDAQ symbol] (NO)
 PLAB Professional and Linguistic Assessment Board (AIE)
 PLAC Placebo [Medicine]
 Plac Placentinus [Deceased, 1192] [Authority cited in pre-1607 legal
 work] (DSA)
 PLAC Post-Launch Analysis of Compliance [NASA]
 Plac Abbrev Placitorum Abbreviatio [Latin A publication] (DLA)
 Plac Ang Nor Bigelow's Placita Anglo-Normanica [A publication] (DLA)
 PLACE Place [Commonly used] (OPSA)
 PLACE Positioner Layout and Cell Evaluator [Robotics]
 PLACE Position Location and Aircraft Communication Equipment